- Home
- COYA vs ARMP Comparison
COYA vs ARMP Comparison
Compare COYA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- ARMP
- Stock Information
- Founded
- COYA 2020
- ARMP 2016
- Country
- COYA United States
- ARMP United States
- Employees
- COYA N/A
- ARMP N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COYA Health Care
- ARMP Health Care
- Exchange
- COYA Nasdaq
- ARMP Nasdaq
- Market Cap
- COYA 98.5M
- ARMP 73.2M
- IPO Year
- COYA 2022
- ARMP N/A
- Fundamental
- Price
- COYA $6.48
- ARMP $1.97
- Analyst Decision
- COYA Strong Buy
- ARMP Strong Buy
- Analyst Count
- COYA 4
- ARMP 1
- Target Price
- COYA $16.25
- ARMP $7.00
- AVG Volume (30 Days)
- COYA 143.6K
- ARMP 11.6K
- Earning Date
- COYA 05-08-2025
- ARMP 05-06-2025
- Dividend Yield
- COYA N/A
- ARMP N/A
- EPS Growth
- COYA N/A
- ARMP N/A
- EPS
- COYA N/A
- ARMP N/A
- Revenue
- COYA $9,554,315.00
- ARMP $5,467,000.00
- Revenue This Year
- COYA N/A
- ARMP $23.87
- Revenue Next Year
- COYA $56.22
- ARMP N/A
- P/E Ratio
- COYA N/A
- ARMP N/A
- Revenue Growth
- COYA N/A
- ARMP 34.92
- 52 Week Low
- COYA $4.75
- ARMP $1.80
- 52 Week High
- COYA $10.69
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- COYA 49.74
- ARMP 46.78
- Support Level
- COYA $6.21
- ARMP $1.81
- Resistance Level
- COYA $6.96
- ARMP $2.16
- Average True Range (ATR)
- COYA 0.69
- ARMP 0.13
- MACD
- COYA -0.03
- ARMP -0.01
- Stochastic Oscillator
- COYA 27.16
- ARMP 43.24
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.